Rising Leaders

From solving delivery challenges for Moderna's COVID-19 vaccine to pioneering the next generation of programmable medicines, the 2025 Rising Leader provides mid-career reflections.

The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.

A 25-year-old's “naive optimism” becomes the driving force behind one of biopharma's most ambitious AI ventures.

The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.

Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Karen Rodriguez Lorenc has overseen linvoseltamab's development and subsequent approvals in Europe and the US. She talked to In Vivo about how patient-centric drug development philosophy is core to her leadership, and why she doesn't believe in failure.

Neha Krishnamohan, CFO of Artiva Biotherapeutics, brings Wall Street precision to biotech innovation, helping lead the company through a successful IPO while advancing NK cell therapies for cancer and autoimmune diseases.

As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.